The notices it replaced
- Reissues: PA-22-176 PHS 2022-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 2 steps back: PA-21-259 PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 3 steps back: PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 4 steps back: PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed
- 5 steps back: PA-18-574 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 6 steps back: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 11 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 12 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 13 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 14 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 15 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-24-245.
Who won it before
7,600 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,293,102,824 in first-year total cost, median $298,379.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]284
- Special Emphasis Panel[ZRG1 ETTN-G (12)]236
- Special Emphasis Panel[ZRG1 IMST-H (15)]202
- Special Emphasis Panel[ZRG1 IDM-V (12)]185
- Special Emphasis Panel[ZRG1 IMST-B (12)]179
Most frequent institutions
- PHYSICAL SCIENCES, INC48
- EPICYPHER, INC.47
- AFFINERGY, LLC31
- LYNNTECH, INC.29
- MINNESOTA HEALTHSOLUTIONS CORPORATION29
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Assay development for the assessment of pregnancy risks in early pregnancy2R44EB033715-02 | ARMANT, DAVID RANDALLDREWLO, SASCHA | AKNA HEALTH LLC, MI | $1,949,879 | ZRG1 |
| 2025 | Platform for Optimizing Yield and Quality of Therapeutic AAV Vector Manufacturing via Synthetic Helper Genes1R44GM158472-01 | HUANG, CHARLIE | SYNVIVIA, INC., CA | $1,640,169 | ZRG1 |
| 2025 | eiF2B Activators to Treat Noise-Induced Hearing Loss2R44DC020069-02A1 | CHOUCHANE, MALEKDAHL, RUSSELL | JACARANDA BIOSCIENCES, INC., CA | $1,554,254 | ZRG1 |
| 2025 | Minimizing myocardial damage and loss of cardiac function post myocardial infarction using Targeted PKC inhibitors 002 and 004.2R44HL160338-02 | ARGENTIERI, THOMASYOUNG, LINDON H | YOUNG THERAPEUTICS, LLC, PA | $1,488,899 | ZRG1 |
| 2025 | Extended-release injectable gel for multi-day treatment of postoperative pain2R44GM145020-02 | OVERSTREET, DEREK JAMES | SONORAN BIOSCIENCES, INC., AZ | $1,479,276 | ZRG1 |
| 2025 | Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts2R44AG084351-02 | CRAVENS, AARON | REVEL PHARMACEUTICALS INC., CA | $1,364,162 | ZRG1 |
| 2025 | The Development of Tabletop Brain-Mapping Platform2R44MH129132-03 | RAGAN, TIMOTHY M. | TISSUEVISION, INC., MA | $1,335,696 | ZRG1 |
| 2025 | A novel agent for preventing fatty degeneration of muscles in LGMD2B2R44AR081168-02 | FLOER, MONIQUE | ADVERTENT BIOTHERAPEUTICS, INC., MI | $1,292,847 | ZRG1 |
| 2025 | Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options2R44HG013456-02 | SCHERER, ANDREAS | GOLDEN HELIX, INC., MT | $1,264,651 | ZRG1 |
| 2025 | A unified eligibility application and determination system to increase Ryan White linkage to care and retention in care by reducing structural barriers and facilitating client engagement1R44MH136864-01A1 | HEDGCOCK, BOB HARRISON | GROUPWARE TECHNOLOGIES, LLC, WI | $1,243,071 | ZRG1 |
| 2025 | A Novel Instrument and Consumables for Quality Control in Next Generation Sequencing1R44HG014079-01 | REED, JASON C | EVIZIA INC, VA | $1,234,692 | ZRG1 |
| 2025 | Development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma1R44CA298512-01 | COOPER, COLLEEN DOYLE | CELDARA MEDICAL, LLC, NH | $1,228,902 | ZRG1 |
| 2025 | TissueReM: Whole-Organism, Real-time Decision-enabled 3D Tissue Imaging and Recovery for Molecular Analysis2R44GM145205-02 | BRADY-KALNAY, SUSANN MGARGESHA, MADHUSUDHANA | BIOINVISION, INC., OH | $1,221,189 | ZRG1 |
| 2025 | Validation of next-generation TMS system optimizing for widely scalable, personalized treatment of depression1R44MH136880-01A1 | DOWNAR, JONATHAN ALEXANDER STEWART | AMPA INC., CA | $1,199,261 | ZRG1 |
| 2025 | AI-linked cytomics-on-a-chip to enable near-real time identification and management of oral lichenoid lesions in primary care1R44DE033934-01 | CHRISTODOULIDES, NICOLAOS JOSEPHMCDEVITT, JOHN T | ORALIVA, INC., FL | $1,178,476 | ZRG1 |
| 2025 | Improving Speed and Cost of Entry for Holographic Optogenetics2R44MH111463-04 | HOY, CHRISTOPHER LUK | MEADOWLARK OPTICS, INC., CO | $1,120,423 | ZRG1 |
| 2025 | Development of a Novel Biosensor to Accelerate Investigations of the Gut Microbiome2R44TR003744-02A1 | NICHOLS, DYLAN | BIOMESENSE, INC., IL | $1,117,161 | ZRG1 |
| 2025 | Development of Deep Learning Tools for Widely-Available, Inexpensive Diagnosis of Coronary Microvascular and Vasomotor Dysfunction1R44HL178315-01 | MOODY, JONATHAN BRYAN | INVIA, LLC, MI | $1,107,749 | ZRG1 |
| 2025 | High-resolution extended-depth phase-engineered objectives to accelerate spatial 'omics R&D through computational optics2R44GM151926-02 | GAUMER, SCOTT | DOUBLE HELIX OPTICS INC., CO | $1,084,722 | ZRG1 |
| 2025 | Magnetic Lipid Nanoprobe Platform for Rapid, Highly-Efficient, and Cost-Effective Isolation of Extracellular Vesicles from Non-Invasive Bodily Fluids1R44TR005339-01A1 | HE, HONGZHANG | CAPTIS DIAGNOSTICS, PA | $1,077,369 | ZRG1 |
| 2025 | Deep-UV Microscopy for Real-Time Adequacy Analysis of Bone Marrow Aspirates2R44EB035057-02 | POWLESS, AMY J | CELLIA SCIENCE, INC., AR | $1,074,143 | ZRG1 |
| 2025 | KYC, an inhibitor of sickle cell disease's vicious cycle in vaso-occlusive crisis and pain1R44HL178153-01 | NAYLOR, STEPHEN | RENEUROGEN, LLC, WI | $1,045,688 | ZRG1 |
| 2025 | Fundamental Training for Formal and Informal STEM Mentors2R44GM137663-02 | STELTER, REBECCA LYNNSTUMP, KATHRYN N | INNOVATION RESEARCH AND TRAINING, INC., NC | $1,029,219 | ZRG1 |
| 2025 | An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation2R44AA029642-02 | MANCHEM, PRASAD | PLEIOGENIX INC., CA | $1,025,643 | ZRG1 |
| 2025 | Development of a Totally Implanted Left Ventricular Assist Device1R44HL177945-01 | ABER, GREG | CORVION, INC., TX | $1,024,635 | ZRG1 |
| 2025 | Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer1R44CA291285-01A1 | NJAR, VINCENT COLLINS OFUKARAMAMURTHY, VIDYA P | ISOPRENE PHARMACEUTICALS, INC., MD | $1,022,522 | ZRG1 |
| 2025 | Development of novel therapeutics for obesity and type 2 diabetes1R44DK142200-01 | ADAMS, CHRISTOPHER MEBERT, SCOTT MATTHEWMATVEYENKO, ALEKSEY VTALLEY, JOHN JEFFREY | EMMYON, INC., MN | $1,021,719 | ZRG1 |
| 2025 | Development of an effective, low-cost, point-of-care early detection test for oral cancer in low resource settings1R44CA298389-01 | CALIFANO, JOSEPH ACHEN, XI STEVENFRANZMANN, ELIZABETH J | VIGILANT LABORATORIES LLC, FL | $1,021,347 | ZRG1 |
| 2025 | Novel approaches for the treatment of autoimmune disease2R44AI174502-02A1 | KANNANGANAT SIDHARTHAN, SUNIL | ASTERO ERADO INC, TX | $1,019,657 | ZRG1 |
| 2025 | Developing and Evaluating Visual, Auditory, and Tactile and Text Digital Thematic Map Viewer to Provide Blind and Low Vision Individuals Full Access to Thematic Maps for the First Time1R44EY036316-01A1 | BIGGS, BRANDON | XR NAVIGATION INC., CA | $1,009,268 | ZRG1 |
| 2025 | Cloud/Web-Based Platform for Quantitative SPECT Reconstruction of Therapeutic Radionuclides1R44CA291419-01A1 | FREY, ERIC C.GHALY, MICHAEL | RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC, MD | $1,003,173 | ZRG1 |
| 2025 | A first-in-class product for the clearance of high-risk human papillomaviruses1R44AI188623-01 | THURMAN, ANDREA RIES | DARE BIOSCIENCE, INC., CA | $1,000,000 | ZRG1 |
| 2025 | Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients1R44AI184225-01A1 | STASKO, NATHAN ALLAN | VAST THERAPEUTICS, INC., NC | $1,000,000 | ZRG1 |
| 2025 | Using Targeted, Controlled High Frequency Energy for Treatment of Onychomycosis1R44AI188772-01 | KING, LAURASCHEFELKER, RICHARD WILLIAM | BIACURE THERAPIES, INC., WI | $1,000,000 | ZRG1 |
| 2025 | Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail1R44AI188855-01 | YEN, MINMIN | PHAGEPRO, INC., MA | $1,000,000 | ZRG1 |
| 2025 | An intravascular Bioartificial Pancreas (iBAP)2R44DK104299-04 | BLAHA, CHARLES | SILICON KIDNEY, LLC, CA | $1,000,000 | ZRG1 |
| 2025 | Air Plasma Sterilization Device with Plasma-in-Lumen Technology2R44FD007709-02 | AGARWAL, PRAWAL | ADVANCED COOLING TECHNOLOGIES, INC., PA | $999,890 | ZRG1 |
| 2025 | OvaReady: An automated microfluidic oocyte retrieval and denudation device2R44HD105529-04 | OZKUMUR, ISMAIL EMRE | AUTOIVF, INC., MA | $997,028 | ZRG1 |
| 2025 | IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents1R44CA298522-01 | STRANGE, GARY | EF THERAPEUTICS CORP., FL | $984,830 | ZRG1 |
| 2025 | Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials2R44GM148111-02 | DOTY, FRANCIS DAVID | DOTY SCIENTIFIC, INC., SC | $982,970 | ZRG1 |
| 2025 | ENT-based Approach to Cervical Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea1R44HL178050-01 | GELFAND, MARK | CORIDEA, LLC, NY | $982,086 | ZRG1 |
| 2025 | Accurate Point of Care Liver Disease Diagnostics, Phase II2R44DK135225-02 | PRADO, PABLO JSIRLIN, CLAUDE B | LIVIVOS INC., CA | $947,354 | ZRG1 |
| 2025 | Manufacturing Development and Commercial Readiness of an Adeno-Associated Virus-Based Gene Therapy for the Treatment of Leber Congenital Amaurosis Type 11R44EY037156-01 | MOUILLESSEAUX, KEVIN P | ATSENA THERAPEUTICS, INC., NC | $870,675 | ZRG1 |
| 2025 | Bearingless flux reversal motor for neonatal and pediatric extracorporeal life support applications1R44HL178134-01 | CAHALAN, PATRICK THOMAS | ENSION, INC., PA | $870,467 | ZRG1 |
| 2025 | Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity1R44NS141534-01 | SIMAO, FABRICIOZHANG, HONGKANG | QUIVER BIOSCIENCE INC., MA | $862,420 | ZRG1 |
| 2025 | Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes2R44DK129875-04 | TANGNEY, JARED RYLAN | BIOLINQ INCORPORATED, CA | $853,587 | ZRG1 |
| 2025 | Mucus and ALI Models of the Human Intestine2R44DK130708-02 | BOAZAK, ELIZABETHSIMS, CHRISTOPHER ELDRIDGE | ALTIS BIOSYSTEMS, INC., NC | $835,939 | ZRG1 |
| 2025 | Low-Cost Platform Technology for Rapid Isolation of Peripheral Blood Mononuclear Cells2R44GM139391-02A1 | HUANG, LOTIEN RICHARD | CG SCIENTIFIC, INC., MA | $833,381 | ZRG1 |
| 2025 | Smart Cavity Creator Drill for Lumbar Interbody Fusion: Direct to Phase II1R44AR085500-01 | MIRZA, SOHAIL K | PEER TECHNOLOGIES, PLLC, DC | $830,712 | ZRG1 |
| 2025 | High Content Screening for Bifunctional Chimera Biologics1R44AI188872-01 | VALENTE, LIZ | HELIGENICS INC, NV | $807,664 | ZRG1 |
| 2025 | VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other solid tumors1R44CA291444-01A1 | SHOWALTER, RICHARD EDWARD | VELORUM THERAPEUTICS INC., TX | $772,293 | ZRG1 |
| 2025 | Dynamical Diffraction Analysis for 3D Electron Crystallography2R44GM148105-02 | BROMBERG, RAQUEL | LIGO ANALYTICS, INC., TX | $762,936 | ZRG1 |
| 2025 | Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis1R44CA298064-01 | GEORGE, TAD | RARECYTE, INC., WA | $658,336 | ZRG1 |
| 2025 | Auto-calibrating, Air Quality Monitoring System2R44OH012498-02 | PATEL, SANJAY V | SEACOAST SCIENCE, INC., CA | $541,648 | ZRG1 |
| 2025 | Bioinspired Green Glycolipids as Fugitive Dust Mitigation Agents2R44ES034319-02 | BOXLEY, CHETT J | GLYCOSURF, INC., UT | $511,412 | ZRG1 |
| 2025 | High bandwidth all-optical electrophysiology1R43MH139287-01 | KILBORN, KARL | 3 I, CO | $505,311 | ZRG1 |
| 2025 | Tough Adhesive Sealants for Vascular Surgery1R43HL176353-01A1 | FREEDMAN, BENJAMIN ROSSKWON, PHOEBE S | LIMAX BIOSCIENCES INC, MA | $464,229 | ZRG1 |
| 2025 | A Digital Biomarker for ALS - Pison Neural Biosensor1R44NS137933-01A1 | BLACKWELL, MEGAN H. | PISON TECHNOLOGY, INC., MA | $459,097 | ZRG1 |
| 2025 | Advanced culture and recording system for long-term electrophysiological profiling in human brain organoids1R43MH139259-01 | KIPKE, DARYL R | NEURONEXUS TECHNOLOGIES, MI | $449,228 | ZRG1 |
| 2025 | Magnetic Rotational Platform for Coronary Lesions1R43HL178364-01 | BACH, RICHARD GORDONCREIGHTON, FRANCIS MILTON | UNANDUP, LLC, MO | $413,595 | ZRG1 |
| 2025 | Rapid and Automated Dissociation of Tumor Tissue for Single Cell Diagnostics1R43TR005720-01 | ZOBI, AHMED NABIL | SYNTR HEALTH TECHNOLOGIES, LLC, CA | $406,500 | ZRG1 |
| 2025 | AntiXero: An extended duration solution for cancer-associated dry mouth.1R43DE034316-01 | HUBER, JOSEPH | ANTIXERO, NC | $406,496 | ZRG1 |
| 2025 | Breakthrough High-Accuracy, High-Throughput Colorectal Cancer Screening Platform1R43CA298515-01 | DRISCOLL, MARK DAVID | INTUS BIOSCIENCES LLC, CT | $405,973 | ZRG1 |
| 2025 | Cyclic Immunofluorescent Imaging in Live Cells1R43CA298597-01 | PETERSON, HANNAH MARIE | APERTURE BIO, INC., MA | $404,994 | ZRG1 |
| 2025 | Development of a Novel Armored CAR-T Immunotherapeutic for Pancreatic Cancer1R44CA298704-01 | ALTMAN, GARY G.RAFIQ, SARWISH | CAMBIUM ONCOLOGY LLC, GA | $400,835 | ZRG1 |
| 2025 | Allogeneic cell and gene therapy for neuroendocrine tumors1R43CA291373-01A1 | DOERING, CHRISTOPHER BRADLEYPETRICH, BRIAN GSPENCER, H TRENT | EXPRESSION THERAPEUTICS, GA | $400,000 | ZRG1 |
| 2025 | AI-powered engineering and analysis of cyanobacterium vesicles targeting gastrointestinal cancer1R43CA298194-01 | SANG, LIYUN JESSICA | ACCURE HEALTH, INC., MA | $400,000 | ZRG1 |
| 2025 | Point-of-care autologous CAR-T cell manufacturing1R43CA298530-01 | LIU, YU-TSUENG | AEROCYTEK, INC., CA | $400,000 | ZRG1 |
| 2025 | Point-of-need screening device for lung cancer in low-resource settings1R43CA291315-01A1 | MEYERSON, NICHOLAS RYAN | DARWIN BIOSCIENCES, INC., CO | $399,998 | ZRG1 |
| 2025 | Epithelial-Mesenchymal Transition Signature Markers (EMTsm) with Machine Learning-Based Analysis as a Predictor of Metastatic Prostate Cancer1R43CA298410-01 | HOMAN, HARVEY D | METASTX LLC, PA | $399,954 | ZRG1 |
| 2025 | ASHES: Assessing Smoking BeHavior with ThErmal Sensing to Prevent Relapse1R43CA298750-01 | ALSHURAFA, NABILDONG, HARRISON | SENSEWHY, INC., IL | $399,891 | ZRG1 |
| 2025 | Head-worn low intensity focused ultrasound (LIFU) device for enhancing sleep in substance use disorder (SUD)1R43DA062460-01 | MAHADEVAN, RAJIV | ATTUNE NEUROSCIENCES, INC., CA | $399,739 | ZRG1 |
| 2025 | iPSC-derived human neurons and OUD medications development1R43DA062459-01 | GOMEZ-GALENO, JORGE E.NAKANISHI, NOBUKI | CHEMREGEN INC, CA | $399,536 | ZRG1 |
| 2025 | FLASH-pulse: A versatile multiplexed tissue imaging solution for research on aging1R43AG092073-01 | M'SAAD, ONS | PANLUMINATE INC., CT | $397,902 | ZRG1 |
| 2025 | Development of Novel Engineered Native Bacteria (ENB) for the Treatment of Familial Adenomatous Polyposis1R43CA291510-01A1 | KELLER, GILBERT A- | ENDURE BIOTHERAPEUTICS, INC., CA | $392,827 | ZRG1 |
| 2025 | Mirame Salud: Immersive Diabetes Self-Management Training for Latino Americans1R43MD020239-01 | HARRIS, RONALD IRWINMITCHELL, SUZANNE | SEE YOURSELF HEALTH, LLC, MA | $385,816 | ZRG1 |
| 2025 | HOMEals: A Science-Based Clinical Decision Support System for Nutrition in IDD Group Homes1R43HD117514-01 | HUMPHRIES, KATHLEENRIGLES, BETHANY | GOOD NUTRITION IDEAS, LLC, OR | $385,000 | ZRG1 |
| 2025 | CRISPR-based depletion method for resolving pseudogene contamination in Next Generation Sequencing (NGS) based genetic testing1R43HG014080-01 | BROWN, KEITH | JUMPCODE GENOMICS, CA | $383,748 | ZRG1 |
| 2025 | Development of an accessible Cognitive Behavioral Therapy digital therapeutic for individuals with Long COVID1R43NR021082-01A1 | RANDA, LAURA | TOIVOA, INC, FL | $383,159 | ZRG1 |
| 2025 | Design and Development of an Advanced Functional MRI Software as Medical Device (SaMD) forClinical Trials and Therapeutic Applications in Neuropsychiatry1R44MH136867-01A1 | SETTON, RONI ASTERN, EMILY | CERETYPE NEUROMEDICINE IN, MA | $380,375 | ZRG1 |
| 2025 | Integrating AI nowcasting models with digital communications to reduce RSV infections in rural areas1R43NR021380-01A1 | MCQUIGGAN, SCOTT | SOCIAL CASCADE, LLC, NC | $378,893 | ZRG1 |
| 2025 | Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease1R44EY037132-01 | DYKSTRA, BRADFORD | STELLULAR BIO, INC., MA | $356,485 | ZRG1 |
| 2025 | Paradigm-changing, versatile, scalable and cost-effective technology for monthly injections of peptide drugs1R43GM157830-01 | KRISHNAN, VISHALAKSHI | ASKO THERAPEUTICS, INC., MI | $350,027 | ZRG1 |
| 2025 | Development of a Viral Vector Sizing Tool to Improve Gene Therapy Analytics and Reduce the Cost of Drug Development1R43TR005330-01A1 | PEREZ LORENZO, LUIS JAVIER | NANOENGINEERING CORPORATION, FL | $349,909 | ZRG1 |
| 2025 | Platform technology for delivery of stabilized therapeutic microbes in powders with high water activity1R43HD117653-01 | ANSELMO, AARON C | VITAKEY, INC., DC | $349,759 | ZRG1 |
| 2025 | A Novel Approach to Eliminate Length Impurities for High-Quality mRNA Production1R43TR005424-01 | BHASKARAN, HARI | CISTERNA BIOLOGICS, INC., CA | $349,746 | ZRG1 |
| 2025 | Arginine-Polyamine Pathway Inhibitor for Treatment of ADPKD1R44DK141418-01A1 | VITEK, MICHAEL PETER | REGENNOVA, INC., NC | $349,325 | ZRG1 |
| 2025 | The Next Wave of Asthma Therapeutics1R43HL177843-01 | BASSAGANYA-RIERA, JOSEP | BIOTHERAPEUTICS, INC., VA | $347,608 | ZRG1 |
| 2025 | In vitro metabolite profiling with vibrational phase-contrast imaging1R43GM157792-01 | HANNINEN, ADAM M | TRESTLE OPTICS LLC, CA | $330,076 | ZRG1 |
| 2025 | High-throughput kinetic system for small-molecule drug discovery1R43TR005404-01 | BERNARD, MARK AGUIRRE | CAPIENDA BIOTECH, LLC, CA | $329,272 | ZRG1 |
| 2025 | Novel procedure and technology for treatment of BPH1R43DK139847-01A1 | SHARMA, TUSHAR | VIVIFI MEDICAL LLC, TX | $325,000 | ZRG1 |
| 2025 | Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism1R44DK142244-01 | SETHURAMAN, VASU V | SYNTIS BIO INC, MA | $324,984 | ZRG1 |
| 2025 | Development of amyloid conformer-targeting technologies in type 2 diabetes mellitus1R43DK142506-01 | GRAHAM, W VALLEN | NUCB1 HOLDINGS LLC, CA | $324,793 | ZRG1 |
| 2025 | Motorized Girth Adjustable Dilator with Dilation and Pressure Measurement for Anorectal Disorders, Designed to Improve Patient Adherence to Treatment via Static-Passive Stretching1R43DK141400-01A1 | JAYOL, BENJAMIN | LUMINA MEDICAL LLC, CA | $324,678 | ZRG1 |
| 2025 | Characterization of a novel non-hallucinogenic psilocybin derivative for alcohol use disorder1R44AA031925-01 | GULICK, DANIELLESALM, JACQUELINEWITOWSKI, CHRISTOPHER G | TERP LIFE, LLC, FL | $320,263 | ZRG1 |
| 2025 | Intraarticular injection of Wnt inhibitor for osteoarthritis therapy1R43AR085490-01 | CHEN, MO | WNT SCIENTIFIC, LLC, NY | $314,363 | ZRG1 |
| 2025 | Fast multicolor confocal fluorescence imager for neural network mapping1R43MH136847-01A1 | YOO, HYEJIN | PHYSICAL SCIENCES, INC, MA | $314,113 | ZRG1 |
| 2025 | GuidedOR: A Real-Time Medication Safety Software Platform for the Operating Room1R44LM014736-01 | NANJI, KAREN C | GUIDED CLINICAL SOLUTIONS, INC., MA | $313,819 | ZRG1 |
| 2025 | NanoSafe Tested™ Facilities: Point-of-Need Exposure Assessment for Ultrafine Particulates, Microplastics, and Engineered Nanomaterials in Production Environments1R43ES037180-01 | HILL, WILLIAM CARY | ITA INTERNATIONAL LLC, VA | $313,372 | ZRG1 |
| 2025 | Real time speech enhancement/noise reduction for the hearing impaired1R43DC022500-01 | HEALY, ERIC WTYSON, MATTHEW | NEURAL EAR INC, OH | $313,372 | ZRG1 |
| 2025 | Bispecific biologic for rheumatoid arthritis therapy1R43AR085475-01 | STANFORD, STEPHANIE | KNOUBIS BIO, INC., CA | $312,323 | ZRG1 |
| 2025 | Engineering a physiologically-tuned reservoir intravaginal ring releasing lactic acid for the treatment and prevention of bacterial vaginosis1R43AI189008-01 | KUSHIRO, KEIICHIRO | MUCOMMUNE, LLC, NC | $310,136 | ZRG1 |
| 2025 | A Novel Anti-infective Therapy for Treating Periodontitis1R43DE034614-01 | FANGER, NEIL AHALSEY, CORTNEY | VIRTICI, LLC, WA | $309,038 | ZRG1 |
| 2025 | Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery1R43GM157920-01 | FENG, PO-LUN | OSEM FLUIDICS INC, CA | $306,873 | ZRG1 |
| 2025 | Meeting the cost and privacy demands for detecting Anabolic Androgenic Steroid doping in youth athletics with rationally designed nuclear receptor BioAssays1R43DA059306-01A1 | SCHAUFELE, FRED J | XCELLASSAY, INC., CA | $306,872 | ZRG1 |
| 2025 | Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes1R43DK141319-01 | CARTER, CALVIN | GEMINII, INC., IA | $306,872 | ZRG1 |
| 2025 | PEACE Platform for Non-Invasive Narrative Neuromodulation (Personalized Evocative Audiovisual Content for Everyone)1R43DA062438-01 | GUTTMAN, JEREMY | BIOMOTIVATE, LLC, PA | $306,872 | ZRG1 |
| 2025 | A novel pediatric prosthetic foot for functional multi-axial mobility during active play1R43HD117457-01 | ALLYN, KATHERYN JOFICANHA, EVANDRO MAICONMAITLAND, MURRAY E. | KATE ALLYN PROSTHETIC RESEARCH, WA | $306,869 | ZRG1 |
| 2025 | Epigenetic Compounds Stimulating Dental Bone Repair1R43DE034602-01 | KENNEDY, PAUL DOUGLAS | CAYMAN CHEMICAL COMPANY, INC., MI | $306,868 | ZRG1 |
| 2025 | Using scalable ultrasonic nano-emulsification to improve pharmacokinetic properties of the natural product curcumin.1R43AT013043-01 | PESHKOVSKY, ALEXEY | INDUSTRIAL SONOMECHANICS, LLC, NY | $306,865 | ZRG1 |
| 2025 | High-content study to analyze the nutritional value of natural products for healthy aging1R43AT013187-01 | MONDAL, SUDIP | VIVOVERSE, LLC, TX | $306,793 | ZRG1 |
| 2025 | Advanced Side Impact Head Protection Technology for Child Safety Seats1R43HD117515-01 | SEIFERT, SARA | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $306,776 | ZRG1 |
| 2025 | Development of a GBP-based glycosylation analysis system1R43GM157786-01 | HAAB, BRIAN B.ZHANG, JIAN | Z BIOTECH, LLC, CO | $306,710 | ZRG1 |
| 2025 | CraniaMap: Joint Solution for Auto-Segmentation and Landmarking from CBCT Scans1R43DE034322-01 | HAN, WADE | THER-AI LLC, FL | $306,633 | ZRG1 |
| 2025 | SkillFlix for Dental Professionals: Video-based Microskills Training to Improve Dental Professionals' Response to Problem Behaviors of Pediatric Patients with IDD1R43DE034648-01 | KUHN, TAMARA J.SCHIEBER, ELIZABETH | DFUSION, INC., CA | $306,618 | ZRG1 |
| 2025 | Free-Breathing Dynamic Cardiopulmonary Function Imaging System to use with Xenon MRI1R43HL178239-01 | EMAMI, KIARASH | SPINHANCE, LLC, PA | $306,530 | ZRG1 |
| 2025 | Preclinical development of VAX024 - a novel targeted combination STING agonist/oncolytic agent1R43CA298595-01 | GIACALONE, MATTHEW | VAXIION THERAPEUTICS, INC., CA | $306,265 | ZRG1 |
| 2025 | Drug Screening Platform in the Light-Responsive Human Eye1R43EY037154-01 | ALLEN, JORDANVINBERG, FRANS | EYESCREEN, INC., UT | $306,118 | ZRG1 |
| 2025 | Podocyturia based assay as a predictive biomarker for systemic vascular diseases1R43HL177857-01 | BADR, KAMAL | TEUCER DIAGNOSTICS, INC., NE | $306,101 | ZRG1 |
| 2025 | A point-of-care device for the determination of homocysteine (Hcy), the Hcy Now1R43TR005426-01 | HARPER, ROBERT | ANALYTICAL DIAGNOSTIC SOLUTIONS, INC., NJ | $305,352 | ZRG1 |
| 2025 | Developing novel 3D printed grafts for nasal reconstruction1R43DE034651-01 | HOLLISTER, SCOTT JMAKHIJA, HANSAZOPF, DAVID ADAM | MOBIUS BIOTECH LLC, GA | $305,320 | ZRG1 |
| 2025 | A Real-time, Automated Maternal Hemorrhage Risk Assessment Platform Using Artificial Intelligence1R43HD117484-01 | MALAKOUTI, SALIM | NOMA AI INC., PA | $305,292 | ZRG1 |
| 2025 | AirPen: A Wearable Sampler for Airborne Hazards in support of Disaster Response Research1R43ES037202-01 | TRYNER, JESSICA | ACCESS SENSOR TECHNOLOGIES, LLC, CO | $305,260 | ZRG1 |
| 2025 | Combinatorial pipeline for discovery of anti-GPCR Nanobodies1R43GM157811-01 | SZENT-GYORGYI, CHRISTOPHER STEPHAN | BIOCOGNON LLC, PA | $303,024 | ZRG1 |
| 2025 | Synthetic biology approaches for bio-orthogonal labeling of circular RNAs1R43GM157885-01 | LITKE, JACOB | CHIMERNA THERAPEUTICS INC., NY | $302,605 | ZRG1 |
| 2025 | METAVEST: Advanced Biomimetic Personal Cooling for Enhancing Heat Safety Among High-Risk Workers1R43OH012845-01 | RAHMAN, ARIF | HAWAI'I INNOVATION INC., HI | $302,424 | ZRG1 |
| 2025 | Clinical validation of Duoseq, a Swiss army knife genomic approach to diagnosis of blood cancers1R43CA298055-01 | DAVE, SANDEEPHAPP, LANIE ELIZABETH | DATA DRIVEN BIOSCIENCE INC, NC | $300,682 | ZRG1 |
| 2025 | NoWeigh: Development of a Physical Activity Promotion Mobile App for WomenBased on Body Neutrality and Self-Determination Theory1R43DK142209-01 | NUSS, KAYLA | KLEIN BUENDEL, INC., CO | $300,172 | ZRG1 |
| 2025 | Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria1R43AI188991-01 | MCGRANE, LAUREL | FIMBRION THERAPEUTICS, INC., MO | $300,001 | ZRG1 |
| 2025 | A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance1R44AI188680-01 | NG, RAINER | BAEBIES, INC., NC | $300,000 | ZRG1 |
| 2025 | The development of a novel antifungal for drug resistance1R43AI188858-01 | MENA, ESTEBAN EDWARD | LIFEPHARMS, INC., CT | $300,000 | ZRG1 |
| 2025 | Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases1R43AI188988-01 | CHAN, KUI KIUPROCKO, ERIK | CYRUS BIOTECHNOLOGY, INC., WA | $300,000 | ZRG1 |
| 2025 | Solid-State Sources for DNP-NMR1R43GM157838-01 | LEAVESLEY, ALISA | VIRGINIA DIODES, INC., VA | $299,996 | ZRG1 |
| 2025 | Disaster-Ready Portable/Standalone Universal Water Purifier based on CER-ICP technology.1R43ES037193-01 | YOON, JUNGHYO | NONA TECHNOLOGIES, INC, MA | $297,815 | ZRG1 |
| 2025 | Use of HIF-1alpha mRNA to Promote Pedicle Flap Healing.1R43AR084352-01A1 | ABRAHAM, JOHN M | ADVANCED MOLECULAR HEALIX INC., MD | $296,256 | ZRG1 |
| 2025 | Novel Antimicrobial Approach to Treat Chemoradiation Resistant Cervical Cancer by Selectively Inhibiting Lactobacillus iners1R43CA297979-01 | LAGENAUR, LAUREL A. | OSEL, INC., CA | $295,881 | ZRG1 |
| 2025 | Improving Caries Diagnosis with Targeted Nanoparticle-Enhanced AI-Assisted Intraoral Imaging1R43DE034324-01 | JONES, NATHAN ANDREW | GREENMARK BIOMEDICAL, INC., MI | $294,632 | ZRG1 |
| 2025 | A Point of Care Test for Babesia microti1R43AI188960-01 | SUTHERLAND, ALAN GORDON | L2 DIAGNOSTICS, LLC, CT | $293,142 | ZRG1 |
| 2025 | BLiPS: Biocompatible Liver in Pigs1R43DK142463-01 | KIEUN, PARK | RENOVATE BIOSCIENCES, INC., MD | $292,116 | ZRG1 |
| 2025 | Targeting endogenous retrovirus Gag genes for biomarker development in type 1 diabetes1R43DK139922-01A1 | DAI, YANG D. | BIOSETTIA, INC., CA | $291,949 | ZRG1 |
| 2025 | Primate epigenetic and senescence biomarkers to advance aging science and anti-aging strategies.1R43AG087835-01A1 | ELSWORTH, JOHN D | VIRSCIO, INC., CT | $291,913 | ZRG1 |
| 2025 | A Subunit Vaccine Against Acinetobacter Baumannii1R43AI189041-01 | DOLLERY, STEPHEN JEFFREY | BIOLOGICAL MIMETICS, INC., MD | $288,360 | ZRG1 |
| 2025 | Bio-Click: A cell-free high-throughput platform for the engineering of enzymatic group transfer reactions1R43GM157956-01 | BILLINGSLEY, JOHN MARTIN | INVIZYNE TECHNOLOGIES, INC., CA | $283,805 | ZRG1 |
| 2025 | A Digital Intervention to Reduce Youth Cannabis Use1R43DA062420-01 | MUENCH, FREDERICK JOHN | MOBILE HEALTH INTERVENTIONS LLC, NY | $280,207 | ZRG1 |
| 2025 | Removal of Palladium from Pharmaceutical Process Chemistry Reactions1R43GM157773-01 | WARNER, BENJAMIN P | PALLADIAS LLC, NM | $280,160 | ZRG1 |
| 2025 | Break Wave lithotripsy to fragment large kidney stones1R44DK141289-01A1 | LEVY, OREN | SONOMOTION, INC., CA | $278,224 | ZRG1 |
| 2025 | A generative-AI-assisted platform for rapidly creating interactive,accurate 3D explainers for all of biomedical science and medicine1R43GM157949-01 | FISHER, JONATHAN | SNORKLE, INC., NY | $270,040 | ZRG1 |
| 2025 | VITaLS: Visual Thinking and Learning Strategies: Enhancing Health Professions Education through Virtual Reality Enabled Art Museum Experiences1R43GM157765-01 | AGARWAL, GAURILARSON, CHRISTINA FAYEMITZOVA-VLADINOV, GRETAOWEN, ROBIN WHITE | MEDIACOMBO, INC., NY | $261,620 | ZRG1 |
| 2025 | Novel Over-the-Scope Platform for Control of Variceal Bleeding1R43DK142274-01 | APPLING, ANTHONY | ENDONAVIS, LLC, KY | $226,192 | ZRG1 |
| 2025 | Development of a proteomic assay for monitoring transplanted cells and tissues1R43DK139879-01A1 | SCHUUR, ERIC R | HEPATX CORPORATION, CA | $175,964 | ZRG1 |
| 2025 | Remediation of acid mine drainage water using selective metal-harvesting membranes1R43ES037224-01 | ULIANA, ADAM | CHEMFINITY TECHNOLOGIES, INC., NY | $138,738 | ZRG1 |
| 2025 | Lactobacillus-vectored Alkaline Phosphatase to Mitigate Alcohol-induced Leaky Gut and LPS Endotoxin Load in the Gut1R43AA032131-01 | GANGAIAH, DHARANESH | BIOMEDIT LLC, IN | $131,654 | ZRG1 |
| 2025 | Head Up CPR and Aortic Occlusion to Improve Survival after Refractory Cardiac Arrest1R43HL177950-01 | LURIE, KEITH | ADVANCEDCPR SOLUTIONS LLC, MN | $1 | ZRG1 |
| 2025 | A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D2R44GM149009-02 | WEINER, MICHAEL P | ABBRATECH, INC., CT | $1 | ZRG1 |
| 2024 | Blood-based Biomarker for Characterizing Progression and Therapeutic Response in Amyotrophic Lateral Sclerosis1R44NS137901-01A1 | EITAN, EREZ | NEURODEX INC, MA | $2,147,016 | ZRG1 |
| 2024 | Subcutaneous Drug Development for Portal Hypertension Ascites2R44DK103553-05 | CASTILLO, GERARDO M. | PHARMAIN CORPORATION, WA | $2,145,275 | ZRG1 |
| 2024 | Optimization of Cannabinoids for Development as FDA-Approved Migraine Therapeutics2R44DA051309-02A1 · under PA-22-176 | PAPPAS, GEORGE | SCHEDULE 1 THERAPEUTICS, INC., IL | $2,019,222 | ZRG1 |
| 2024 | Development of a Novel Hyaluronan Inhibitor for the Treatment of Group 3 Pulmonary Hypertension (PH)1R44HL169052-01A1 · under PA-22-176 | PALADINI, RUDY | HALO BIOSCIENCES, INC., CA | $1,957,305 | ZRG1 |
| 2024 | Platform for Extended Kidney Preservation Via Subnormothermic Perfusion1R44DK139895-01A1 | BARBAS, ANDREW SERGHIOSNEUSNER, ROBERTROY-CHAUDHURY, PRABIR | BIOMEDINNOVATIONS, INC., NC | $1,870,135 | ZRG1 |
| 2024 | Measuring Whole and Tissue Level Bone Strength in men2R44AG071034-03A1 · under PA-22-176 | BURKS, PETERTANG, SIMON YUE-CHEONG | ACTIVE LIFE SCIENTIFIC, INC., CA | $1,716,342 | ZRG1 |
| 2024 | Nourexal™: A Novel Bioenergetic Drug to Increase Donor Heart Utilization1R44HL174138-01A1 | ELGEBALY, SALWA A | NOUR HEART, INC., VA | $1,658,923 | ZRG1 |
| 2024 | Prospective validation of a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy1R44CA291456-01A1 | JORDAN, PETR | ONC.AI, INC., CA | $1,625,000 | ZRG1 |
| 2024 | New Generation of Mitochondrial Uncouplers for the Treatment of Metabolic DIsorders2R44DK127880-02A1 | VU, SIMON | EQUATOR THERAPEUTICS, INC., MO | $1,571,137 | ZRG1 |
| 2024 | Antigen-targeted activation of Topo1 inhibitors via click chemistry1R44CA291345-01A1 | MCFARLAND, JESSE MISCHAMEJIA ONETO, JOSE M | SHASQI, INC., CA | $1,568,070 | ZRG1 |
| 2024 | Develop, Optimize and Commercialize UltraMarathonRT: A new enzyme for unbiased transcriptomic and epitranscriptomic characterization of RNAs regardless of length or composition.1R44GM153078-01A1 | GUO, LI-TAO | RNACONNECT INC, CT | $1,555,946 | ZRG1 |
| 2024 | NX90: A Treatment for Overdose Caused by High Potency Opioids1R44DA061722-01 | VORONKOV, MICHAEL V. | SERODOPA THERAPEUTICS INC, FL | $1,539,426 | ZRG1 |
| 2024 | Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.2R44AG071409-03 | ELIZAROV, ARKADIJ | TRACE-ABILITY, INC., CA | $1,500,000 | ZRG1 |
| 2024 | Remmie.ai a deep learning diagnostic engine for ear-nose throat disease2R44DC020868-02 | ZHANG, JANE | REMMIE, INC., WA | $1,499,051 | ZRG1 |
| 2024 | Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD)1R44NS137943-01 | JEWELL, CHRISTOPHER M | CARTESIAN THERAPEUTICS, INC., MD | $1,496,118 | ZRG1 |
| 2024 | Preclinical assessment of a novel compound for treating radiation-induced oral mucositis2R44DE031464-02 · under PA-22-176 | LLOYD, COLTON JOSEPH | SINOPIA BIOSCIENCES, INC., CA | $1,493,635 | ZRG1 |
| 2024 | Commercialization of the Vital-Dent Regenerative Pulp Therapy1R44DE033313-01A1 | SU, XIAOLI | VIC FOUNDRY, INC., AR | $1,434,831 | ZRG1 |
| 2024 | Preclinical Toxicology Study of Intrathecal VersaMab-101 for spinal cord injury treatment2R44NS127712-02 · under PA-22-176 | SUN, MIAO | VERSAPEUTICS INC, CA | $1,430,030 | ZRG1 |
| 2024 | Late-stage development and de-risking of a novel monoclonal antibody immunotherapy for EGFR-positive solid cancers1R44CA291266-01 | STERN, HOWARD M | TIGATX INC, MA | $1,418,424 | ZRG1 |
| 2024 | A novel approach for treating myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)1R44CA291331-01 | FAN, XIAOMIN | AVANTGEN, INC., CA | $1,398,552 | ZRG1 |
| 2024 | Next Generation Pediatric Neuroimaging (NGPN) Development2R44MH122028-03A1 | CORUM, CURTIS ANDREW | CHAMPAIGN IMAGING, LLC, MN | $1,390,948 | ZRG1 |
| 2024 | IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel strategy for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients1R44HL174171-01 | STRANGE, KEVIN | REVIDIA THERAPEUTICS, INC, ME | $1,358,179 | ZRG1 |
| 2024 | Skin probiotics to treat Netherton Syndrome2R44AR082240-02A1 | ZARGAR, AMIN | RESVITA BIO, INC., CA | $1,330,533 | ZRG1 |
| 2024 | SBIR Phase II: Novel Hyaluronan Enhanced Polymeric Trans-Catheter Aortic Valve2R44HL158387-02A1 | TOMBA, TODD CHARLES | YOUNGHEARTVALVE LLC, GA | $1,325,562 | ZRG1 |
| 2024 | Lazzaro Medical Scaffold System for improved treatment of tracheobronchomalacia1R44HL172325-01A1 | BITZ, DAWN DAWN | LAZZARO MEDICAL, INC., CO | $1,323,708 | ZRG1 |
| 2024 | Resubmission - Development and scale-up of Continuous Countercurrent Tangential Chromatography (CCTC) for next generation AAV vector manufacturing (Direct to Phase II)1R44GM154572-01A1 | SHINKAZH, OLEG | CHROMATAN CORPORATION, MA | $1,304,417 | ZRG1 |
| 2024 | Immunotherapy to deplete key Treg subsets in solid tumors1R44CA295167-01 | BISHAI, WILLIAM RAMSESMURPHY, JOHN R.SUZDAK, PETER DAVID | SONOVAL LLC, MD | $1,293,505 | ZRG1 |
| 2024 | Orphan Non-coding RNA-based Test for Detecting Minimal Residual Disease in Resectable Non-small Cell Lung Cancer1R44CA291369-01A1 | ALIPANAHI, BABAKBEHSAZ, BABAKPATEL, SANDIP PRAVIN | EXAI BIO, INC., CA | $1,280,908 | ZRG1 |
| 2024 | Development of a Minimally Invasive Single Cannulation, Compact Single Port Pulsatile Ventricular Assist Device (sppVAD) for Total LV Support2R44HL158430-02 | TOPAZ, STEPHEN R | W-Z BIOTECH, LLC, KY | $1,280,230 | ZRG1 |
| 2024 | Biochemical and genomic tools to study histone ADP ribosylation signaling1R44GM153000-01 · under PA-22-176 | HUNT, SABRINA ROBINSUN, ZU-WEN | EPICYPHER, INC., NC | $1,274,494 | ZRG1 |
| 2024 | Improved flow cytometry panel design with a novel automated panel design system2R44GM143945-02 | YOUNG, DAREN | FLUOROFINDER, LLC, CO | $1,272,160 | ZRG1 |
| 2024 | Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist1R44HL174192-01A1 | ELSHOURBAGY, NABIL A | SHIFA BIOMEDICAL CORPORATION, PA | $1,267,886 | ZRG1 |
| 2024 | A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing2R44GM134776-04 · under PA-22-176 | HOWELL, DAVID W. | BONDWELL TECHNOLOGIES LP, TX | $1,253,658 | ZRG1 |
| 2024 | Multi-Radical Protein Footprinting (MRPF™) Platform2R44GM142351-02 | WEINBERGER, SCOT RANDY | GENNEXT TECHNOLOGIES, INC., CA | $1,251,300 | ZRG1 |
| 2024 | Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding1R44HL176351-01 | YUK, HYUNWOO | SANAHEAL, INC., MA | $1,249,317 | ZRG1 |
| 2024 | Commercialization of a rapid, automated Hi-C platform for sensitive genomic profiling of multiple cancer sample types1R44HG014126-01 | MUNDING, ELIZABETH | CANTATA BIO LLC, MA | $1,247,028 | ZRG1 |
| 2024 | A Device to Prevent Sudden Unexpected Death in Epilepsy (SUDEP)2R44NS120394-02 | BANSAL, PRANAVLEE, JONG WOO | SOTERYA, INC., MA | $1,244,175 | ZRG1 |
| 2024 | Improving extraction success of FFPE samples with automated and reliable microfluidic sample preparation2R44GM148126-02A1 | FISHER, JAY KENNETH | REDBUD LABS, INC., NC | $1,238,908 | ZRG1 |
| 2024 | R-FIX (Rib-FIXation) Spinal Growth System for Early-onset Spinal Deformity2R44AR080507-02 | BONTHIUS, DANIEL JAMESGROSS, RICHARD H.YAO, HAI | APEX ORTHOPAEDIC TECHNOLOGIES LLC, SC | $1,238,710 | ZRG1 |
| 2024 | Development of a universal gene therapy for hemophilia A or B with or without inhibitors1R44HL174236-01 | MARGARITIS, PARIS | GENEVENTIV THERAPEUTICS, INC., NC | $1,230,198 | ZRG1 |
| 2024 | System for unitary automation of library preparation2R44GM145194-02A1 | FISHER, JAY KENNETH | REDBUD LABS, INC., NC | $1,223,863 | ZRG1 |
| 2024 | A 3D super-resolved platform for rapid and highly multiplexed proteomics2R44MH128999-02 | M'SAAD, ONS | PANLUMINATE INC., CT | $1,219,907 | ZRG1 |
| 2024 | A tunable laser scanning system for rapid analysis of biopharmaceutical formulations1R44GM156127-01 | HASSELL, BRYAN | NIRRIN TECHNOLOGIES INC, MA | $1,219,222 | ZRG1 |
| 2024 | Wearable Monitoring System for Enhancing Rehabilitation Following Rotator Cuff Repair2R44AR078082-02A1 | SHEEAN, GEOFFREY | ACTIVE4D, INC., CA | $1,207,313 | ZRG1 |
| 2024 | EpiScalp: An EEG Analytics Solution to Improve Diagnosis of Epilepsy1R44NS137845-01 | GOTSHALK, ANDREWHARIDAS, BABITHAHOPP, JENNIFER L.SPERLING, MICHAEL R | NEUROLOGIC SOLUTIONS, INC., VA | $1,204,564 | ZRG1 |
| 2024 | A mobile application to offer upfront healthcare prices and automated medical billing for socioeconomically disadvantaged Americans2R44NR021119-03A1 · under PA-22-176 | MARMOUSH, AHMED | HANDL HEALTH LLC, CA | $1,185,981 | ZRG1 |
Showing the 200 most recent of 7,600 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.